Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy

World Health Organisation, 2018, Latest global cancer data, Int. Agency Res. Cancer, 13 International Agency for Research on Cancer, 2019, 1 Couzin-Frankel, 2013, Breakthrough of the year 2013, Cancer immunotherapy., Science., 342, 1432 Hakomori, 2001, Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines, 369, 10.1007/978-1-4615-1267-7_24 Buskas, 2009, Immunotherapy for cancer: synthetic carbohydrate-based vaccines, Chem. Commun. (Camb.), 5335, 10.1039/b908664c Jing, 2019, Overexpression of MUC1 predicts poor prognosis in patients with breast cancer, Oncol. Rep., 41, 801 Danishefsky, 2000, From the laboratory to the clinic: A retrospective on fully synthetic carbohydrate-based anticancer vaccines frequently used abbreviations are listed in the appendix, Angew. Chem. Int. Ed. Engl., 39, 836, 10.1002/(SICI)1521-3773(20000303)39:5<836::AID-ANIE836>3.0.CO;2-I Yin, 2012, Recent development in carbohydrate based anticancer vaccines, J. Carbohydr. Chem., 31, 143, 10.1080/07328303.2012.659364 Wei, 2018, Carbohydrate-based vaccines for oncotherapy, Med. Res. Rev., 38, 1003, 10.1002/med.21493 Feng, 2016, Recent advance in tumor-associated carbohydrate antigens (TACAs)-based antitumor vaccines, ACS Chem. Biol., 11, 850, 10.1021/acschembio.6b00084 Guo, 2009, Recent development in carbohydrate-based cancer vaccines, Curr. Opin. Chem. Biol., 13, 608, 10.1016/j.cbpa.2009.08.010 Riley, 2019, Delivery technologies for cancer immunotherapy, Nat. Rev. Drug Discov., 18, 175, 10.1038/s41573-018-0006-z Lloyd, 1989, Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients, Cancer Res., 49, 3445 Sait, 2017, Anti-GD2 immunotherapy for neuroblastoma, Expert Rev. Anticancer Ther., 17, 889, 10.1080/14737140.2017.1364995 Hung, 2019, GD2-targeted immunotherapy of neuroblastoma, 63 Battula, 2012, Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis, J. Clin. Invest., 122, 2066, 10.1172/JCI59735 Cheever, 2009, The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research, Clin. Cancer Res., 15, 5323, 10.1158/1078-0432.CCR-09-0737 Gillies, 1989, High-level expression of chimeric antibodies using adapted cDNA variable region cassettes, J. Immunol. Methods, 125, 191, 10.1016/0022-1759(89)90093-8 D’Aloia, 2018, CAR-T cells: the long and winding road to solid tumors review-article, Cell Death Dis., 9, 10.1038/s41419-018-0278-6 Rossig, 2001, Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes, Int. J. Cancer, 94, 228, 10.1002/ijc.1457 Richards, 2018, CAR T cell therapy for neuroblastoma, Front. Immunol., 9, 2380, 10.3389/fimmu.2018.02380 Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma, Nat. Med., 14, 1264, 10.1038/nm.1882 Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood., 118, 6050, 10.1182/blood-2011-05-354449 Chen, 2019, Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15, Clin. Cancer Res., 25, 2915, 10.1158/1078-0432.CCR-18-1811 You, 2016, Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells, Sci. China Life Sci., 59, 386, 10.1007/s11427-016-5024-7 Song, 2012, CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo, Blood., 119, 696, 10.1182/blood-2011-03-344275 Craddock, 2010, Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b, J. Immunother., 33, 780, 10.1097/CJI.0b013e3181ee6675 Bocca, 2017, Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model, Oncoimmunology. Caruana, 2015, Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes, Nat. Med., 21, 524, 10.1038/nm.3833 Gargett, 2016, GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade, Mol. Ther., 24, 1135, 10.1038/mt.2016.63 Gibbons, 2012, B7-H1 limits the entry of effector CD8+ T cells to the memory pool by upregulating bim, Oncoimmunology., 1, 1061, 10.4161/onci.20850 Latchman, 2004, PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells, Proc. Natl. Acad. Sci. U. S. A., 101, 10691, 10.1073/pnas.0307252101 Rowe, 2008, PDL-1 blockade impedes T Cell expansion and protective immunity primed by attenuated listeria monocytogenes, J. Immunol., 180, 7553, 10.4049/jimmunol.180.11.7553 Heczey, 2017, CAR T cells administered in combination with lymphodepletion and PD-1 Inhibition to patients with neuroblastoma, Mol. Ther., 25, 2214, 10.1016/j.ymthe.2017.05.012 John, 2013, Blockade of PD-1 immunosuppression boosts CAR T-cell therapy, Oncoimmunology., 2, 10.4161/onci.26286 Cherkassky, 2016, Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition, J. Clin. Invest., 126, 3130, 10.1172/JCI83092 Chong, 2017, PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR, Blood., 129, 1039, 10.1182/blood-2016-09-738245 Thomas, 2016, An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers, PLoS One, 11, 10.1371/journal.pone.0152196 Richman, 2018, High-Affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model, Cancer Immunol. Res., 6, 36, 10.1158/2326-6066.CIR-17-0211 Gargett, 2014, The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T-cells, Front. Pharmacol., 5, 235, 10.3389/fphar.2014.00235 Mitwasi, 2017, Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells, Oncotarget., 8, 108584, 10.18632/oncotarget.21017 Apostolopoulos Vasso, 2004, MUC1: a molecule of many talents, Curr. Trends Immunol., 6, 39 Kufe, 2013, MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches, Oncogene., 32, 1073, 10.1038/onc.2012.158 Ibrahim, 2011, Randomized phase II trial of letrozole plus Anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer, Clin. Cancer Res., 17, 6822, 10.1158/1078-0432.CCR-11-1151 Steentoft, 2018, Glycan-directed CAR-T cells, Glycobiology., 28, 656, 10.1093/glycob/cwy008 Hossain, 2016, Immunological evaluation of recent MUC1 glycopeptide cancer vaccines, Vaccines., 4, 25, 10.3390/vaccines4030025 Taylor-Papadimitriou, 2018, Latest developments in MUC1 immunotherapy, Biochem. Soc. Trans., 46, 659, 10.1042/BST20170400 Wilkie, 2008, Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor, J. Immunol., 180, 4901, 10.4049/jimmunol.180.7.4901 You, 2016, Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells, Sci. China Life Sci., 59, 386, 10.1007/s11427-016-5024-7 Maher, 2009, CAR mechanics: driving T cells into the MUC of cancer, Cancer Res., 69, 4559, 10.1158/0008-5472.CAN-09-0564 Gheybi, 2014, Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer, Tumor Biol., 35, 11489, 10.1007/s13277-014-2483-y Sørensen, 2006, Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance, Glycobiology., 16, 96, 10.1093/glycob/cwj044 Posey, 2016, Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma, Immunity, 44, 1444, 10.1016/j.immuni.2016.05.014 Zhou, 2019, CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth, Front. Immunol., 10, 1, 10.3389/fimmu.2019.01149 Wei, 2017, PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells, Oncoimmunology, 6, 10.1080/2162402X.2017.1284722 Dotti, 2009, Fifteen years of gene therapy based on chimeric antigen receptors: Are we nearly there yet?, Hum. Gene Ther., 20, 1229, 10.1089/hum.2009.142 Büning, 2010, Do CARs need a driver’s license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events, Hum. Gene Ther., 21, 1039, 10.1089/hum.2010.131 Szymczak, 2004, Correction of multi-gene deficiency in vivo using a single “self-cleaving” 2A peptide-based retroviral vector, Nat. Biotechnol., 22, 589, 10.1038/nbt957 Wilkie, 2012, Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling, J. Clin. Immunol., 32, 1059, 10.1007/s10875-012-9689-9 Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat. Biotechnol., 31, 71, 10.1038/nbt.2459 Lanitis, 2013, Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo, Cancer Immunol. Res., 1, 43, 10.1158/2326-6066.CIR-13-0008 Fan, 2015, Bispecific antibodies and their applications, J. Hematol. Oncol., 8, 130, 10.1186/s13045-015-0227-0 Kontermann, 2015, Bispecific antibodies; different formats, Drug Discov. Today, 20, 838, 10.1016/j.drudis.2015.02.008 Bhutani, 2015, Activated T cells armed with bispecific antibodies kill tumor targets, Curr. Opin. Hematol., 22, 476, 10.1097/MOH.0000000000000176 Husain, 2018, Expanding the boundaries of biotherapeutics with bispecific antibodies, BioDrugs., 32, 441, 10.1007/s40259-018-0299-9 Holmes, 2011, Buy buy bispecific antibodies, Nat. Rev. Drug Discov., 10, 798, 10.1038/nrd3581 Yankelevich, 2012, Anti-CD3×anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets, Pediatr. Blood Cancer, 59, 1198, 10.1002/pbc.24237 Xu, 2015, Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody, Cancer Immunol. Res., 3, 266, 10.1158/2326-6066.CIR-14-0230-T Cheng, 2016, Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors, Oncoimmunology, 5, 1, 10.1080/2162402X.2016.1168557 Deppisch, 2017, Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition, Oncotarget., 8, 4520, 10.18632/oncotarget.13888 Katayose, 1996, MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth, Cancer Res., 56, 4205 Modak, 2018, Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: results of a phase I study, Oncoimmunology, 7 Tarek, 2012, Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment, J. Clin. Invest., 122, 3260, 10.1172/JCI62749 Schettini, 2012, Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity, Cancer Immunol. Immunother., 61, 2055, 10.1007/s00262-012-1264-y Li, 2018, Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells, PLoS One, 13, 1 Hoseini, 2017, Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2, Oncoimmunology, 6, 10.1080/2162402X.2017.1320625 Alvarez-Rueda, 2011, A monoclonal antibody to O-Acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity, PLoS One, 6, e25220, 10.1371/journal.pone.0025220 Samraj, 2014, Involvement of a non-human sialic acid in human cancer, Front. Oncol., 4, 33 Inoue, 2010, Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells, Glycobiology, 20, 752, 10.1093/glycob/cwq030